Member Directory

Abcam is a producer and distributor of high quality protein research tools. Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (China), allowing it to serve a global customer base in over 130 countries. Abcam has an online catalogue of over 102,000 products sourced from over 400 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users.

Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. We invest across all stages of company development including early and late-stage venture financing, growth equity and public companies.. Founded in 1973, Abingworth has a lengthy track record of building market leading companies. Our specialist team of 19 professionals has a broad range of skills, including scientific and business expertise as well as investment banking, recruitment and legal knowledge. These resources are made available to portfolio companies. Abingworth has funds under management of over $1.25 billion and offices in London, Menlo Park (California) and Boston.

Air Products was established in 1940 in Detroit, Michigan, on the strength of a simple, but then revolutionary, idea: the on-site concept of producing and selling industrial gases, primarily oxygen. At the time, most oxygen was sold as a highly compressed gas product in cylinders that weighed five times more than the gas itself. Air Products proposed building oxygen gas generating facilities adjacent to large-volume users, thereby reducing distribution costs. The concept of piping the gas directly from the generator to the point of use proved sound and technically solvable.

AMSBIO supplies research products and custom services to the biological and pharmaceutical industries. We sell products for routine laboratory procedures as well as more specific, cutting-edge technology. Areas of specific expertise include physiologically realistic cell culture (including 3D culture), tissues and biorepositories, Zymolyase, glycobiology, lentivirus, ELISA kits and stem cell technology. We also offer custom services in protein expression, histochemistry, peptide/antibody design and 3D culture. With offices in the UK, Germany, Switzerland and the USA, AMSBIO offers fast delivery of material. For more information, please visit www.amsbio.com or contact AMSBIO’s multilingual help team.

Arecor is the world leader at improving the durability of biologic medicines. Using a rational approach to formulation design, Arecor has generated proprietary technology for stabilising therapeutic proteins, antibodies and vaccines. Arecor has partnered with the world’s largest pharmaceutical companies to enable previously impossible delivery and use options for biologics. As an example of how effective these technologies are – in over 90 per cent of the cases – Arecor’s technology can enable: solid-to-liquid re-formulations; removal of cold-chain; high-concentration delivery, e.g. 200+ mg/ml; and co-formulation of incompatible components.

Astex is dedicated to the discovery and development of novel small molecule therapeutics with a primary focus on oncology. The Company, which is a recognised leader in the field of Fragment Based Drug Discovery, is developing a proprietary pipeline of novel therapies and has a number of other programmes partnered with major pharmaceutical companies with products in clinical development. . . In October 2013, Astex was acquired by Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan. . . For more information about Astex please visit http://www.astx.com

AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.. . We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.. . We employ over 61,000 people (46% in Europe, 24% in the North America, 7% in Latin America and 24% in Asia, Africa and Australasia)

Babraham Bioscience Technologies (BBT) is the company that manages and develops the Babraham Research Campus, supporting and promoting the regional and UK bioscience ecosystem. It has responsibility for the administration and commercial development of the site for the benefit of all the tenants including the Babraham Institute.. . The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

Bailey Fisher Executive Search is an independent executive search firm operating globally across life sciences, digital health, technology and private markets. The Life Sciences Practice is led by Iain Hopper. Iain focuses on executive level high-impact hires in pharmaceuticals, biotechnology, digital health and medical devices, partnering with a range of clients from early stage VC backed companies through SMEs to large corporates. Prior to joining Bailey Fisher, Iain lived and worked in Sydney - where he led senior level and executive level roles for 3 of the world's top 10 pharmaceutical and biotech companies - and London, developing a strong network across Australia, SE Asia, the UK and Europe. At Bailey Fisher, Iain works closely with James Houlder, Director of Research. James has extensive experience in executive search within Life Sciences & Digital Health, during 3 years leading research for all assignments in this sector at Bailey Fisher and previously as an in-house recruiter for Illumina and Medimmune.

Main activities are: fundraising for early stage life science companies, helping companies become investment ready; advice on obtaining R&D grants; interim and financial management for early stage companies; and contributing to board decisions as non-executive director. Experience includes raising equity for eight life science companies and obtaining R&D grants for 16 others. Also 12 years managing small companies and a number of non-executive director posts.

Pages